Drug Profile
MORAb 066
Alternative Names: Anticancer monoclonal antibody (MORAb-066) - Janssen Biotech/Morphotek; MORAb-006Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator Centocor Ortho Biotech
- Developer Morphotek
- Class Anti-inflammatories; Anticoagulants; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Thromboplastin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 01 Aug 2018 Discontinued - Phase-I for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Eisai pipeline, August 2018)
- 01 Aug 2018 Discontinued - Phase-I for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Eisai pipeline, August 2018)
- 01 Aug 2018 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Eisai pipeline, August 2018)